JCI insightMay 8, 2026

Gene editing and nanoparticle delivery in key airway cells for cystic fibrosis treatment

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 28, 2026

Abstract

Essence

Base editing plus polymeric nanoparticles corrected a CFTR splice variant and restored clinically meaningful CFTR function in airway cell models relevant to cystic fibrosis.

Evidence

This preclinical airway-cell study used base editor RNAs in primary cystic fibrosis airway cells and polymeric nanoparticle delivery in immortalized and primary airway cultures, with single-cell RNA sequencing showing increased CFTR transcript across epithelial cell types and functional rescue after correction of the 3120+1G>A variant.

Caveat

The results come from cell and airway culture systems centered on one CFTR splice-site variant, so durable in vivo efficacy across patients and airway cell populations remains unproven.

Simplified

Cystic fibrosis (CF) is a life-limiting genetic disorder caused by deleterious variants in the CFTR gene that results in altered mucus impairing the airway epithelia. Durable correction of these variants in airway cells remains a therapeutic challenge for about 10% of individuals unresponsive to CFTR modulators. A common disease-causing CFTR splice site variant, 3120+1G>A, was corrected in primary CF airway cells using base editor RNAs. Single-cell RNA sequencing revealed a remarkable increase in detectable CFTR transcript in most CF airway epithelial cell types resulting in notable enrichment of CFTR-expressing ionocytes and secretory goblet cells. Progenitor basal cell subtypes were edited, but they decreased as a fraction of total cells and CFTR-expressing cells compared with unedited cells. CRISPR base editors delivered by polymeric nanoparticles (PNPs) facilitated functional rescue of CFTR to clinically meaningful levels in immortalized and primary airway cells. PNPs delivered GFP-encoding RNA to progenitor airway cells in fully differentiated airway cultures. Vitronectin was a major component of the PNP corona that formed in vivo, but preincubation with vitronectin did not enhance delivery. Together, these findings validate a scalable, nonviral platform with compelling translational promise for treating CF and other respiratory diseases involving respiratory epithelial cell dysfunction.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

JJG reports a relationship with Dome Therapeutics that includes board membership, consulting or advisory, and equity or stocks. JJG reports a relationship with Cove Therapeutics that includes board membership, consulting or advisory, and equity or stocks. JJG reports a relationship with WyveRNA Therapeutics that includes board membership and equity or stocks. JJG reports a relationship with VasoRx that includes board membership and equity or stocks. GAN reports that he has filed patents US20230235309A1, US11795443B2, WO2025122725A1, and WO2026015609A1. Johns Hopkins University has filed a patent application, WO2024098053A1, based on technology discussed in this article with JJG, SYT, GRC, and EWK as co-inventors.

PubMed

Featured in

CRISPR Gene EditingIssue #36

Gold nanoparticles deliver CRISPR and 2.1 kb DNA templates into blood cells

↗

Gene editing and nanoparticle delivery in key airway cells for cystic fibrosis treatment

Abstract

Full Text

Funding

Competing interests

Featured in

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief

Abstract

Full Text

Funding

Competing interests

Related papers

Featured in

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief